Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effective vaccine for lassa fever.

S P Fisher-Hoch1, L Hutwagner, B Brown

  • 1Special Pathogens Branch, Division of Viral, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Journal of Virology
|July 11, 2000
PubMed
Summary

Developing a Lassa virus vaccine is critical for West Africa. Studies show that targeting both G1 and G2 glycoproteins induces cell-mediated immunity, leading to high survival rates in primates, unlike nucleoprotein vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular magnetic resonance to differentiate veteran athlete's heart with cavity dilatation and mild dilated cardiomyopathy.

European heart journal. Cardiovascular Imaging·2025
Same author

Neutral pressure measurement in TCV tokamak using ASDEX-type pressure gauges.

The Review of scientific instruments·2025
Same author

Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

12/15-Lipoxygenases mediate neuropathic-like pain hypersensitivity in female mice.

bioRxiv : the preprint server for biology·2024
Same author

Shock first, ask questions later….

Acute medicine·2022
Same author

Opportunities to improve the impact of two national clinical audit programmes: a theory-guided analysis.

Implementation science communications·2022

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Lassa fever causes significant mortality in West Africa, with control efforts hampered by conflict.
  • Current vaccine strategies face challenges, as antibody levels don't correlate with protection in humans, and inactivated vaccines are ineffective in primates.

Purpose of the Study:

  • To develop a safe and effective Lassa virus vaccine by inducing a predominantly TH1-type immune response.
  • To evaluate the protective efficacy of vaccinia virus-expressed Lassa virus structural proteins in nonhuman primates.

Main Methods:

  • 44 macaques were vaccinated with Lassa virus structural proteins (nucleoprotein, G1, G2, or combinations) expressed by vaccinia virus.
  • Vaccinated macaques were subsequently challenged with Lassa virus to assess survival rates and immune responses.

Main Results:

  • Vaccination with all structural proteins resulted in 90% survival, while unvaccinated controls had 0% survival.
  • Antibodies to nucleoprotein did not confer protection, with 80% mortality.
  • Immunity against both G1 and G2 glycoproteins was crucial for protection, indicating the importance of cell-mediated immunity.

Conclusions:

  • Effective Lassa virus vaccines require immune responses targeting epitopes on both G1 and G2 glycoproteins.
  • Protection appears to be primarily cell-mediated, not antibody-dependent.
  • Developing and evaluating a Lassa virus vaccine for human use is a humanitarian priority.

Related Experiment Videos